by Instem Team | Jan 14, 2025 | Resources
The ICH S1B WoE directive is a real game-changer for the pharma industry In this White Paper you will learn the importance and significance of the recent ICH S1B Guideline, and how technology-enabled approaches, such as Artificial Intelligence (AI) and Machine...
by Instem Team | Jan 14, 2025 | Resources
Learn how different Genetox data formats can be easily converted to SEND in Submit™ Over the course of this hour-long meeting, Instem’s SEND and Genetox experts will present on a variety of topics, including: The information that needs to go into this dataset...
by Instem Team | Jan 14, 2025 | Clinical, Resources
Learn how to overcome the most troublesome Biostatistics workflows hurdles. There can be many barriers in clinical data analysis that can grind your biometrics team to a standstill delaying your drug development programs. Disjointed systems, unprotected data,...
by Instem Team | Jan 14, 2025 | Resources
What is the preferred approach for predicting carcinogenicity potency of N-nitrosamines? This session will describe the Carcinogenicity Potency Categorization Algorithm (CPCA) that is used by regulators for quickly predicting carcinogenicity potency of...
by Instem Team | Jan 14, 2025 | Resources
Let’s re-imagine the carcinogenicity assessment In the fast-paced and cost-conscious ‘drug to market’ race, momentum can be gained by implementing a Weight of Evidence (WoE) to negate unnecessary preclinical testing. We will present results from a...
